Miraculins Inc. (TSX VENTURE:MOM), a medical diagnostic company

focused on acquiring, developing and commercializing diagnostic tests

and risk assessment technologies for unmet clinical needs, announces

that distinguished U.S. Cardiologist Dr. Henry A. Solomon, MD, FACP,

FACC has been appointed to the PreVu Medical Advisory Board.

Dr. Solomon received his MD from Columbia University College of

Physicians and Surgeons (New York, NY), completed his internship and

residency at Montefiore Hospital and Medical Centre (New York, NY),

and his Cardiology Fellowship at the New York Hospital - Cornell

Medical Center (New York, NY). He is a Diplomate of both the American

Board of Internal Medicine and the American Board of Cardiovascular

Disease. He was most recently the Chief Medical Officer, Business

Development, of the American College of Cardiology, which has over

37,000 members including physicians, registered nurses, clinical nurse

specialists, nurse practitioners, physician assistants, doctors of

pharmacology and practice administrators specializing in

cardiovascular care.

Dr. Solomon continues to serve as Senior Medical Advisor to the

American College of Cardiology (which publishes the prestigious, peer

reviewed Journal of the American College of Cardiology), as well as

Chair of the College's Professional and Corporate Consortium. He is

also a highly sought-after lecturer and medical guest commentator and

has appeared on The Oprah Winfrey Show, ABC's 20/20 and Nightline,

CBS's Face the Nation, and NBC's The Today Show.

"I am very pleased to become a member of the PreVu Medical Advisory

Board," said Dr. Solomon. "The PreVu Non-Invasive Skin Cholesterol

Test is a remarkable new risk assessment technology to assist in the

earlier detection and primary prevention of coronary artery disease.

It provides further risk stratification against the traditional

determination of 'global risk', and can consequently help better

identify patients with subclinical cardiovascular disease who could

benefit from more intensive primary prevention measures to prevent a

first coronary event."

"Dr. Solomon is a distinguished American Cardiologist, Researcher and

medical mind," said Christopher J. Moreau, President and CEO of

Miraculins. "His years of experience across the cardiology spectrum

will help guide us as we introduce PreVu to world markets and work to

educate Health Care Professionals everywhere about this significant

new biomarker and the test designed to measure it. His experience will

also be especially valuable as we take steps to strategically

introduce PreVu into the U.S. marketplace and we will be updating the

market shortly regarding our American sales and marketing plans."

About Dr. Henry A. Solomon

Dr. Henry A. Solomon's current and past affiliations include

memberships in the American Medical Association; the American Heart

Association; the New York State Medical Society; the New York Country

Medical Society; the Royal Society of Medicine (Affiliate, London);

the American Federation for Clinical Research; and the American

Society of Hypertension. He is a Clinical Associate Professor of

Medicine at The Weill Cornell Medical College of Cornell University in

New York, and is additionally a Fellow of the American College of

Physicians and the American College of Cardiology.

A highly published researcher and prolific author, Dr. Solomon has

also served as Chairman of the Editorial Board of Masters in

Cardiology, 1983-1996; as Editor-in-Chief of Management Options in

Cardiology, 1989; as Editor-in-Chief of Living with Angina, 1981-1983;

as Editor-in-Chief of Cardiology Counterpoint, 1981-1985; and has

served on the Editorial Board of The American Journal of Sports &

Medicine. He is the author of a best-selling book, "The Exercise

Myth", which has been translated into several languages and sold in

many countries.

Dr. Solomon possesses additional academic and medical credits far too

numerous to detail in this forum and has been listed in the

prestigious "Guide to America's Top Cardiologists".

About The PreVu Non-Invasive Skin Cholesterol Test

PreVu is a non-invasive risk assessment technology that evaluates the

additional risk a person may have for coronary artery disease (CAD) by

conveniently and painlessly testing their skin cholesterol level. High

levels of skin cholesterol have been shown to be correlated to CAD as

measured by stress test, angiography, coronary calcium, and carotid

intima-media thickness, inflammatory markers of vascular disease,

previous heart attack incidents and Framingham risk score.

About Miraculins Inc.

Miraculins is a medical diagnostic development company focused on

acquiring and advancing non-invasive tests for unmet clinical needs.

The Company's PreVu test is a revolutionary new coronary artery

disease (CAD) risk assessment technology that measures cholesterol

levels in a patient's skin non-invasively, painlessly and without the

need for fasting. The PreVu Non-Invasive Skin Cholesterol Point of

Care (POC) Test technology has been cleared for sale by Health Canada

and CE-Marked and Registered in the European Union. PreVu has

previously been successfully test marketed in North America on a

limited basis. Miraculins additional programs include a research use

only ELISA kit for the detection of PSP94; and a suite of biomarkers

to aid in the early detection of the devastating disease of pregnancy

known as preeclampsia. The Company's preeclampsia program is being

advanced in partnership with Alere, Inc. (NYSE:ALR) (formerly known as

Inverness Medical Innovations), one of the world's largest diagnostic


Caution Regarding Forward-Looking Information

Certain statements contained in this press release constitute

forward-looking information within the meaning of applicable Canadian

provincial securities legislation (collectively, "forward-looking

statements"). These forward-looking statements relate to, among other

things, our objectives, goals, targets, strategies, intentions, plans,

beliefs, estimates and outlook, including, without limitation, our

anticipated future operating results, and can, in some cases, be

identified by the use of words such as "believe," "anticipate,"

"expect," "intend," "plan," "will," "may" and other similar

expressions. In addition, any statements that refer to expectations,

projections or other characterizations of future events or

circumstances are forward-looking statements.

These statements reflect management's current beliefs and are based on

information currently available to management. Certain material

factors or assumptions are applied in making forward-looking

statements, and actual results may differ materially from those

expressed or implied in such statements. Important factors that could

cause actual results to differ materially from these expectations

include, among other things: Miraculins' early stage of development,

lack of product revenues and history of operating losses,

uncertainties related to clinical trials and product development,

rapid technological change, uncertainties related to forecasts,

competition, potential product liability, additional financing

requirements and access to capital, unproven markets, supply of raw

materials, income tax matters, management of growth, partnerships for

development and commercialization of technology, effects of insurers'

willingness to pay for products, system failures, dependence on key

personnel, foreign currency risk, risks related to regulatory matters

and risks related to intellectual property and other risks detailed

from time to time in Miraculins' filings with Canadian securities

regulatory authorities, as well as Miraculins' ability to anticipate

and manage the risks associated with the foregoing. Additional

information about these factors and about the material factors or

assumptions underlying such forward-looking statements may be found in

the body of this news release. Miraculins cautions that the foregoing

list of important factors that may affect future results is not

exhaustive. When relying on Miraculins' forward-looking statements to

make decisions with respect to Miraculins investors and others should

carefully consider the foregoing factors and other uncertainties and

potential events.

These risks and uncertainties should be considered carefully and

prospective investors should not place undue reliance on the

forward-looking statements. Although the forward-looking statements

contained in this press release are based upon what management

believes to be reasonable assumptions, Miraculins cannot provide

assurance that actual results will be consistent with these

forward-looking statements. Miraculins undertakes no obligation to

update or revise any forward-looking statement.

@ PreVu is a registered trademark of Miraculins Inc. All Rights

Reserved. 2011.

Neither TSX Venture Exchange nor its Regulation Services Provider (as

that term is defined in the policies of the TSX Venture Exchange)

accepts responsibility for the adequacy or accuracy of this release.